Core Viewpoint - Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, reported its preliminary results for the year ended December 31, 2025, focusing on innovative treatments for gastrointestinal cancers and type 1 diabetes [3][11]. Company Overview - Biodexa is headquartered in Cardiff, UK, and is listed on NASDAQ under the ticker BDRX. The company is developing products targeting gastrointestinal cancers, including Familial Adenomatous Polyposis (FAP) and Gastrointestinal Stromal Tumors (GIST) [3][11]. - The lead development programs include eRapa for FAP and Non-Muscle Invasive Bladder Cancer, MTX240 for GIST, and tolimidone for type 1 diabetes [3][11][12]. Development Pipeline - The company has transitioned from a drug delivery focus to a therapeutics company, with all pipeline assets currently at the clinical stage [12]. - The development pipeline includes: - eRapa: undergoing a Phase 3 trial for FAP and a Phase 2 study for Non-Muscle Invasive Bladder Cancer [16][19]. - MTX240: in-licensed from Otsuka, ready for Phase 1 studies targeting GIST [12][38]. - Tolimidone: in Phase 2a for type 1 diabetes, with potential disease-modifying effects [31][42]. Clinical Trials and Milestones - In 2025, significant milestones included the initiation of the Phase 3 Serenta trial for eRapa, with 168 patients expected to be enrolled across multiple sites in the US and Europe [23][37]. - The company received FDA Fast Track designation and Orphan Drug Designation for eRapa, enhancing its development prospects [37]. - The first patient in the Phase 3 trial was enrolled in August 2025, with European enrollment commencing in December 2025 [36][37]. Financial Overview - R&D expenditure for 2025 was £3.96 million, a decrease of 27.2% from £5.44 million in 2024, reflecting a strategic focus on key projects [53][55]. - The company reported a net cash inflow of £6.87 million for the year, compared to a net outflow of £4.30 million in 2024, indicating improved financial management [62][65]. - Administrative costs increased to £4.84 million, driven by professional fees and foreign exchange movements [56]. Market Potential - The global GIST market is valued at approximately $1.3 billion, with an expected growth rate of 6-10% annually through 2032, driven by rising incidence and new therapeutic options [28]. - There is a significant unmet medical need for GIST patients who develop resistance to existing treatments, positioning MTX240 as a potential solution [27][39]. Strategic Partnerships and Financing - The company entered a License and Collaboration Agreement with Otsuka for MTX240, which includes exclusive global development rights, excluding Japan [38]. - Biodexa secured a $20 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Phase 3 program for eRapa, contingent on a company match [46][74].